Sufentanil–medetomidine anaesthesia compared with fentanyl/fluanisone–midazolam is associated with fewer ventricular arrhythmias and death during experimental myocardial infarction in rats and limits infarct size following reperfusion

Abstract

German

Spanish

French

To improve infarct healing following myocardial infarction in humans, therapeutic interventions can be applied during the inflammatory response. Animal models are widely used to study this process. However, induction of MI in rodents is associated with high mortality due to ventricular fibrillation (VF) during coronary artery ligation. The anaesthetic agent used during the procedure appears to influence the frequency of this complication. In this retrospective study, the effect on ventricular arrhythmia incidence during ligation and infarct size following in vivo reperfusion of two anaesthetic regimens, sufentanil–medetomidine (SM) and fentanyl/fluanisone–midazolam (FFM) was evaluated in rats. Anaesthetics were administered subcutaneously using fentanyl/fluanisone (0.5 mL/kg) with midazolam (5 mg/kg) (FFM group, n = 48) or sufentanil (0.05 mg/kg) with medetomidine (0.15 mg/kg) (SM group, n = 47). The coronary artery was ligated for 40 min to induce MI. Heart rate and ventricular arrhythmias were recorded during ligation, and infarct size was measured via histochemistry after three days of reperfusion. In the SM group, heart rate and VF incidence were lower throughout the experiment compared with the FFM group (6% versus 30%) (P < 0.01). Fatal VF did not occur in the SM group whereas this occurred in 25% of the animals in the FFM group. Additionally, after three days of reperfusion, the infarcted area following SM anaesthesia was less than half as large as that following FFM anaesthesia (8.5 ± 6.4% versus 20.7 ± 5.6%) (P < 0.01). Therefore, to minimize the possibility of complications related to VF and acute death arising during ligation, SM anaesthesia is recommended for experimental MI in rats.

Keywords

ischaemia anaesthesia arrhythmias sufentanil medetomidine

Ischaemic heart disease is currently the leading cause of death worldwide.¹ There is increasing evidence that targeting the inflammatory response that occurs following cardiac ischaemia/reperfusion (I/R) injury associated with myocardial infarction (MI), contributes to improved cardiac healing.^2–8 Animal models are particularly useful for studying the inflammatory response and putative therapeutic interventions following I/R injury.

The acute inflammatory response triggered by cardiac I/R injury in rats mimics the human response. Therefore, rats are a common choice for use as an MI research model, where myocardial ischaemia is induced via temporary coronary artery ligation.⁹ Induction of cardiac I/R requires a relative long period of surgical anaesthesia. Although this animal model has been used in numerous studies, induction of myocardial ischaemia is frequently associated with sudden death due to the development of ventricular tachycardia (VT) and eventually ventricular fibrillation (VF).^10,11 To avoid unnecessary use of animals, the model requires refinement to minimize fatal loss of animals when ischaemic damage is induced. In general, the anaesthetic effect on heart rate (HR), incidence of ventricular arrhythmias during ischaemia and infarct size can vary widely,¹¹ emphasizing the importance for the selection of anaesthetic regimen. Generally, different agents are combined to provide all of the components of general anaesthesia such as loss of consciousness, analgesia, reflex activity suppression and muscle relaxation.¹² Additionally, using a mixture of agents lowers the required dose per drug thereby diminishing dose-dependent side-effects which can result in a reduction of the total volume of anaesthetic required for injection.¹²

In this study, the response of the anaesthetic mixtures of sufentanil–medetomidine (SM) and fentanyl/fluanisone–midazolam (FFM) in rats during cardiac I/R surgery was evaluated retrospectively. Fentanyl or the more potent opioid sufentanil, in combination with the alpha-2 agonist medetomidine, have both been reported to be effective anaesthetic combinations in rats, providing excellent analgesia together with a prolonged sedation time.^13,14 Moreover, the effect of SM can be reversed rapidly using butorphanol and atipamezole, which greatly speeds recovery.¹² Fentanyl/fluanisone is a veterinary anaesthetic combination of the μ-opioid agonist fentanyl which abolishes pain perception, and the neuroleptic fluanisone which reduces undesirable side-effects of fentanyl and provides additional sedative effects.¹² Addition of midazolam to fentanyl/fluanisone provides muscle relaxation, and this combination results in a surgical plane of anaesthesia.¹⁵ Both SM and FFM induce a longer analgesia and sedation time after a single injection compared with those anaesthetics such as pentobarbital or ketamine–xylazine that are most widely used in cardiac I/R studies.^13,14 To select the best agent for use in cardiac I/R rat models, the effect on HR and ventricular arrhythmias during 40 min of coronary artery ligation together with the infarct size after three days of reperfusion was evaluated in this study.

Animals, materials and methods

Male Wistar rats (n = 95, aged 6–8 weeks; Harlan Laboratories, Horst, The Netherlands) weighing between 350 and 420 g were used. Male rats were used in this study because observations in our laboratory showed a higher lethality in female rats following cardiac I/R (unpublished data). The animals were allowed to acclimatize for at least one week before surgery and were group-housed (3–4) in conventional type IV cages (Tecnilab-BMI, Someren, The Netherlands) placed in one room. Following surgery, the rats were placed individually in conventional type III cages for 48 h to allow proper healing of the scar. Cages were bedded with Lignocel (J Rettenmaier and Söhne, Zutphen, The Netherlands) enriched with Enviro-dri® paper fibers (Tecnilab-BMI). A 12 h:12 h light–dark cycle was maintained and room temperature was kept between 20 and 22℃ and humidity at 50 ± 5%. Water and a commercially pelleted diet (2016 Teklad Global 16% protein rodent diet; Harlan Laboratories) were provided ad libitum. Animals were tested and shown to be negative for all major rodent pathogens as described in the Federation of European Laboratory Animal Science Associations (FELASA) guidelines.^16,17

Ethical permissions

The studies were approved in 2012 and 2014 by the VU University Amsterdam animal ethics and welfare committee. VU University Amsterdam is licensed according to the 2010/63/EU guidelines. The rats involved in this study were accommodated and cared for in conformity with the guidelines described in Appendix A of the European Treaty Series No. 123 of the European Convention for the protection of vertebrate animals used for experimental and other scientific purposes.

Anaesthesia and analgesia

The rats were anaesthetized with either SM (n = 48) or FFM (n = 47). The rats were not randomized and observers were not blinded since this study assessed ventricular arrhythmia data retrospectively from two separate studies using either SM or FFM anaesthesia. Medetomidine (1.0 mg/mL, Sedastart; AST Farma, Oudewater, The Netherlands) was diluted 1:6⅔ with water for injection (Frensenius Kabi Nederland BV, Den Bosch, The Netherlands) and mixed with sufentanil (0.05 mg/mL; Hameln Pharmaceuticals GmbH, Hameln, Germany). The SM mixture was administered subcutaneously (SC) in a volume of 1.5 mL/kg containing 0.05 mg/kg sufentanil and 0.15 mg/kg medetomidine. Fentanyl/fluanisone (0.5 mL/kg of Hypnorm® containing 0.315 mg/mL fentanyl and 10 mg/mL fluanisone; Janssen Pharmaceuticals, Tilburg, The Netherlands) and 5 mg/kg midazolam (5 mg/mL, Dormicum®; Roche, Almere, The Netherlands) were administered SC using two separate syringes. The rats were weighed prior to the anaesthetic injections. To minimize stress, they were injected next to their cages to which the rats were returned until the anaesthesia had taken effect. Immediately following the surgical procedure, the rats were injected SC with 1 mL 0.9% NaCl to compensate for surgery-related fluid loss. In addition, after completion of the surgical procedure, the rats anaesthetized with SM received 0.2 mg/kg butorphanol (Torbugesic-Vet; Zoetis BV, Capelle aan de IJssel, The Netherlands) freshly mixed with 0.5 mg/kg atipamezole (Atipamezole-HCl; Eurovet Animal Health, Bladel, The Netherlands) SC to rapidly antagonize the sufentanil and medetomidine, respectively. One hour after the administered antagonists, buprenorphine (0.03–0.05 mg/kg, Temgesic® diluted 1:9 in 0.9% NaCl; Reckitt Benckiser BV, Hoofddorp, The Netherlands) was administered SC to provide a longer period of analgesia than butorphanol.¹⁸ Although buprenorphine also reverses the effects of sufentanil, its onset of action is relatively slower. Hence, butorphanol was administered primarily as the reversal agent. Rats anaesthetized with FFM received buprenorphine immediately after completion of the procedure. Buprenorphine administration was continued in both groups every 8–12 h for 48 h following surgery to prolong analgesia. The rats were kept on a heating pad, and their HR and respiratory frequency were closely monitored until recovery from the anaesthesia.

Surgical procedure

After the loss of their pedal withdrawal reflex, the rats were intubated with a 16 gauge tube (B Braun Introcan; Oss, The Netherlands) for ventilation. They were placed on a heating pad to maintain body temperature at 37℃. Following intubation, the rats were ventilated using 40% oxygen (UNO micro ventilator-03; UNO, Zevenaar, The Netherlands), their fur was removed locally and their skin was disinfected with 70% v/v ethanol. All operations were performed by the same surgeon during daytime using freshly autoclaved instruments. Cardiac I/R was induced as described previously.² In brief, a left thoracotomy was performed between the third and fourth ribs. To prevent the lungs from collapsing, positive end expiratory pressure (PEEP) of 2 mbar was maintained using a microventilator. During surgery, the effects of anaesthesia were assessed by closely monitoring the HR, heart rhythm and signs of hypercapnia such as changes in respiratory rate and depth caused by carbon dioxide accumulation. To induce MI, the left anterior descending artery was ligated using a 6-0 prolene suture. After 40 min of ischaemia, the suture was removed to allow reperfusion and the thorax was closed using two sutures and maximal lung pressure. On average, total surgery time was 65 min. Welfare of the animals was assessed daily until termination.

Ventricular arrhythmia assessment

During the entire ligation period, HR as well as sinus rhythm (SR) of the rats were monitored using an electrocardiogram set according to Einthoven I ECG (ADInstruments, Oxford, UK). HR measurements were noted at three time-points, namely (1) at start of the surgery, (2) 10 min after ligation, and (3) after 10 min of reperfusion. These time-points were representative of HR during the baseline, ischaemia and reperfusion periods, respectively. The ventricular arrhythmias induced by ischaemia were denoted in accordance with the Lambeth conventions, namely¹⁹

VT: defined as a sequence of four or more ventricular complexes with a rate faster than the resting sinus rate and with an autonomous return to SR;

VF: defined as a rate where QRS complexes could not be distinguished individually and return to SR did not occur autonomously; and

fatal VF: defined when rats died during ligation as a cause of VF and did not respond to mechanical defibrillation performed manually on the heart.

Infarct size measurements

Following three days of reperfusion, a subgroup of the rats were killed humanely by excision of the heart under deep anaesthesia using 5% isoflurane (SM anaesthesia n = 9, FFM anaesthesia n = 6). The hearts of the other rats were assessed at various times after reperfusion, depending on the design of other studies, and the data obtained from these hearts are not included in this study. The heart was excised and cut into five equal slices. Three of these slices were fixed in 4% formalin and embedded in paraffin, and the other two were snap-frozen in liquid nitrogen. To discriminate viable myocardium from diseased myocardium, histochemical staining with phosphotungstic acid haematoxylin was performed on all five slices as described previously.² The stained slides were scanned and the infarcted area and total heart area were marked manually using the Pannoramic viewer programme (version 1.15.4; 3D Histech Ltd, Budapest, Hungary). The average infarct size of all five slices was calculated as a percentage of the complete transverse heart section.

Statistical analysis

The incidence of ventricular arrhythmias during the monitoring period was noted as categorical data, presented as a percentage (%), and treatment comparisons were made using a chi-squared test. Post hoc analyses were performed to test for associations between two groups using a Fisher’s exact test. HR and infarct size data were distributed normally and differences between the two groups were analysed using a Student’s t-test. HR data are presented with the mean and the standard error of mean (SEM) and infarct size data are presented as box plots with median, 25th–75th percentiles (boxes) and 5th–95th percentiles (whiskers). HR data at different time-points within groups were compared using a paired Student’s t-test. Differences between results were considered to be statistically significant if the two-sided P value was < 0.05. The statistical analysis was performed using Statistical Packages for Social Sciences software (IBM SPSS 22.0.0.0 for Windows; IBM Corp, Armonk, NY, USA).

Results

Heart rate

Rats anaesthetized with SM had a significantly lower HR compared with FFM anaesthesia at baseline (246 ±26 versus 323 ± 37 bpm, P < 0.001), during ischaemia (261 ± 31 versus 301 ± 25 bpm, P < 0.01) and following reperfusion (264 ± 12 versus 317 ± 36 bpm, P < 0.01), as shown in Figure 1. Comparison of HR in rats within the same group at different time-points did not show any significant differences.

Figure 1.

Heart rate (HR) in rats during experimental myocardial infarction using SM or FFM anaesthesia. HR in rats following anaesthesia administration of either SM or FFM at the start of surgery (Baseline), 20 min after surgery initiation (Ischaemia) and 60 min after surgery initiation (Reperfusion). These time-points are representative for HR during that period. Coronary artery ligation was initiated at 10 min following surgery initiation. HR data are presented with the mean and the standard error of mean (SEM). ***P < 0.001, **P < 0.01 measured between SM and FFM groups using a Student’s t-test. BPM: beats per minute, SM: sufentanil–medetomidine, FFM: fentanyl/fluanisone–midazolam.

Incidence of ventricular arrhythmias during 40 min of ischaemia

Figure 2 shows the incidence of ventricular arrhythmias during 40 min of ligation in rats anaesthetized with SM or FFM. In the SM group, 38% (18/48) of the rats maintained SR during ligation, which was significantly higher than the 2% (1/47) in the FFM group rats (P < 0.001). The remainder of the rats all experienced either VT or VF during ligation. The occurrence of VT during ischaemia did not differ between the two anaesthesia groups. However, the percentage of rats receiving SM that experienced VF during ligation was significantly lower compared with the FFM rats (6% [3/48] and 30% [14/47], P < 0.01). Moreover, no rats died during ligation when SM anaesthesia was used, whereas 25% (12/47) of the rats anaesthetized with FFM developed fatal VF (P < 0.001).

Figure 2.

Incidence of ventricular arrhythmia during 40 min of coronary artery ligation. Incidence of VT, VF or death (in percentage) in rats during 40 min of coronary artery ligation using SM or FFM anaesthesia. ***P < 0.001, **P < 0.01 as compared between groups. VT: ventricular tachycardia, VF: ventricular fibrillation, fatal VF: death during ischaemia, SM: sufentanil–medetomidine, FFM: fentanyl/fluanisone–midazolam.

Infarct size after three days of reperfusion

Figure 3(a) shows the percentages of the infarcted area of the heart measured on day 3 following cardiac I/R surgery in a subgroup of rats using SM and FFM. The infarcted area of SM anaesthetized rats (8.5 ± 6.4%) was significantly smaller compared with the infarcted area of the rats using FFM anaesthesia (20.7 ± 5.6%) (P < 0.01). Figure 3(b) shows a representative photograph of a smaller infarcted area after cardiac I/R in rats using SM compared with FFM.

Figure 3.

Infarct size in rats following three days of reperfusion. (a) Infarct size (in percentage) following 40 min of ischaemia and three days of reperfusion in rats using SM or FFM anaesthesia. Infarct size data are presented as box plots with median, 25th–75th percentiles (boxes) and 5th–95th percentiles (whiskers). (b) PTAH stain of paraffin embedded hearts showing the pink infarcted area (i) marked with a red line and the viable myocardium (v) in purple. PTAH: phosphotungstic acid haematoxylin, SM: sufentanil–medetomidine, FFM: fentanyl/fluanisone–midazolam.

Discussion

To study putative therapeutic interventions during infarct healing following cardiac I/R injury, animal models are of considerable importance. However induction of MI in rodents can be associated with a high mortality rate, due mostly to the development of VF during coronary artery ligation, resulting in the use of a larger number of animals per study. In this study it has been shown for the first time that the use of SM anaesthesia in rats is associated with a lower HR and a reduced incidence of ventricular arrhythmias and deaths during 40 min of ligation compared with FFM anaesthesia, and is not associated with death during VF. In addition, the infarct size was significantly smaller after three days of reperfusion in the SM group compared with the FFM group. Thus VF occurs less, and the survival rate is higher, when rats undergo cardiac I/R surgery under SM anaesthesia compared with FFM anaesthesia.

As this was a retrospective study, the experimental design was not randomized or blinded, and this presents a limitation of the study. Rats in the FFM group underwent surgery 1.5 years before the rats in the SM group. However all other variables were kept similar, such as the surgeon performing the procedure, the rat strain, age and sex, as well as the entire surgical methodology, including the instruments used and the operating room. Moreover, the analyses of the ventricular arrhythmias and the infarct size were carried out in an identical manner. Notwithstanding this, the possibility that the lack of randomization could have affected the outcome of the results cannot be completely excluded.

The reduction of ventricular arrhythmias observed using SM anaesthesia could be the result of a smaller infarct size following coronary occlusion. Activated opioid receptors are suggested to provide cardioprotection as they are also described to be involved in ischaemic pre- and postconditioning.^20–23 Ischaemic preconditioning, first reported in 1986, demonstrates how brief periods of hypoxia prior to prolonged coronary occlusion protect against infarction.²⁴ In ischaemic postconditioning, brief periods of ischaemia are applied at the start of reperfusion, and this has been shown to be as effective in preventing myocardial injury as preconditioning.²⁵ In rats, it has been demonstrated that non-selective blocking of the opioid receptor abolishes both ischaemic preconditioning²⁰ and postconditioning²² protective effects. These results increased the interest in unravelling the mechanism of opioid receptor activation during the pre- or postconditioning of an ischaemic period. It remains debatable which particular opioid receptor is involved. Several studies have shown that κ- and δ-opioids are involved in cardioprotection whereas μ-opioids, the receptors of sufentanil and fentanyl, have been suggested to be less involved.^26–28 However, it has been demonstrated in rats that pharmacological postconditioning by sufentanil administration early during reperfusion contributes to infarct size reduction after 2 h of reperfusion.²⁹ Moreover, pre- and postconditioning with sufentanil prevent hypoxia-induced myocardial damage in cultured contracting human arterial trabeculae, a cell culture which mimics the beating human myocardium.³⁰ These results appear to be in line with the reduced infarct size as observed following SM anaesthesia in this study, since SM was present during both ligation and early reperfusion, as SM anaesthesia was antagonized after early reperfusion. Nevertheless, only the rats anaesthetized with SM received butorphanol following the surgical procedure, which reverses µ-opioid but simultaneously provides analgesia via agonist activity at the κ-opioid receptor.¹⁴ Activation of κ-opioids in particular are suggested to be involved in attenuating cardiac I/R injury related to pre- or postconditioning.^28,31,32 Conversely, another study has shown that activated κ-opioid receptors do not mediate the beneficial ischaemic preconditioning effect.³³ Notwithstanding this, we cannot rule out the possibility that administration of butorphanol could have influenced the infarct size in the SM group. Since blood oxygen saturation levels were not monitored in this study, the possibility that hypoxia could have been a confounding factor on VF incidences during ligation cannot be excluded.

In addition, the presence of the alpha-2 agonist medetomidine in the SM mixture could have suppressed ventricular arrhythmias during ligation. A meta-analysis pointed out that the use of alpha-2 agonists in patients who undergo cardiac surgery can reduce perioperative mortality as a consequence of ventricular arrhythmias, and also reduces MI.³⁴ Stimulation of the alpha-2 adrenoceptors in the central nervous system results in a reduction of norepinephrine outflow and thereby directly dampens the sympathetic tone.³⁵ This can contribute to the development of bradycardia,^35,36 which is a common side-effect of medetomidine, especially when combined with opioids.^36,37 Moreover, bradycardia has been correlated with the suppression of VT and VF.³⁸

Dampening of the sympathetic tone to reduce cardiac arrhythmias and mortality following cardiac surgery is widely used in clinical settings by administration of beta blockers, which antagonize beta adrenoceptors.^39,40 Recently, it was demonstrated that suppression of the sympathetic tone early after MI via administration of beta-blockers before reperfusion, reduced infarct size and resulted in an improved cardiac recovery following MI.⁴¹ This suggests that administration of beta-blockers during ischaemia is beneficial to cardiac outcomes. However, even though both stimulation of alpha-adrenoceptors and inhibition of beta-adrenoceptors results in suppression of the sympathetic tone, it is still debatable whether this in turn results in an equal response to ventricular arrhythmia and infarct size following ischaemia.⁴²

Whether the production of a smaller infarcted area as observed in this study when using SM anaesthesia would offer a better infarct model is dependent upon the goals of the specific study. For example where therapeutic interventions aiming to reduce the infarcted area are to be evaluated, a larger infarcted area might produce larger treatment effects. However, the considerable decrease in mortality rate when using SM anaesthesia enables the use of fewer animals. An alternative approach would be to consider altering the coronary artery ligation method, in order to increase the infarcted area, if this was necessary.

Based upon the results in this study it is recommended that SM anaesthesia should be used for experimental cardiac I/R surgery in rats. Our results show that a change of anaesthetics can consistently influence the infarct size following cardiac I/R, and that SM anaesthesia avoids loss of animals by preventing complications related to VF and acute death during coronary artery ligation. This results in a reduction in the number of animals needed for cardiac I/R studies. To unravel the mechanism of VF suppression by SM anaesthesia is of considerable interest, not only for laboratory use, but also for clinical use in patients with coronary artery diseases.

Footnotes

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Ellis ter Horst was funded by The Netherlands Heart Institute (project 140.01). This research received no specific grant from any funding agency in the public or commercial sectors.

References

Nowbar

Howard

Finegold

Asaria

Francis

. 2014 global geographic analysis of mortality from ischaemic heart disease by country, age and income: statistics from World Health Organisation and United Nations. Int J Cardiol 2014; 174: 293–298.

van Dijk

Krijnen

Vermond

et al.

Inhibition of type 2A secretory phospholipase A2 reduces death of cardiomyocytes in acute myocardial infarction. Apoptosis 2009; 14: 753–763.

Van Dijk

Vermond

Krijnen

et al.

Intravenous clusterin administration reduces myocardial infarct size in rats. Eur J Clin Invest 2010; 40: 893–902.

Frangogiannis

. Targeting the inflammatory response in healing myocardial infarcts. Curr Med Chem 2006; 13: 1877–1893.

Maekawa

Anzai

Yoshikawa

et al.

Prognostic significance of peripheral monocytosis after reperfused acute myocardial infarction: a possible role for left ventricular remodeling. J Am Coll Cardiol 2002; 39: 241–246.

Nahrendorf

Pittet

Swirski

. Monocytes: protagonists of infarct inflammation and repair after myocardial infarction. Circulation 2010; 121: 2437–2445.

van der Laan

Hirsch

Robbers

et al.

A proinflammatory monocyte response is associated with myocardial injury and impaired functional outcome in patients with ST-segment elevation myocardial infarction: monocytes and myocardial infarction. Am Heart J 2012; 163: 57–65.e2.

van der Laan

Nahrendorf

Piek

. Healing and adverse remodelling after acute myocardial infarction: role of the cellular immune response. Heart 2012; 98: 1384–1390.

Cray

Zaias

Altman

. Acute phase response in animals: a review. Comp Med 2009; 59: 517–526.

10.

Koplan

Stevenson

. Ventricular tachycardia and sudden cardiac death. Mayo Clin Proc 2009; 84: 289–297.

11.

Shekarforoush

Fatahi

Safari

. The effects of pentobarbital, ketamine–pentobarbital and ketamine–xylazine anesthesia in a rat myocardial ischemic reperfusion injury model. Lab Anim 2016; 50: 179–184.

12.

Flecknell

. Laboratory animal anaesthesia, 4th ed. Oxford: Elsevier/Academic Press, 2015.

13.

Hedenqvist

Roughan

Flecknell

. Sufentanil and medetomidine anaesthesia in the rat and its reversal with atipamezole and butorphanol. Lab Anim 2000; 34: 244–251.

14.

Flecknell

Liles

. Fentanyl and medetomidine anaesthesia in the rat and its reversal using atipemazole and either nalbuphine or butorphanol. Lab Anim 1992; 26: 15–22.

15.

Flecknell

Mitchell

. Midazolam and fentanyl–fluanisone: assessment of anaesthetic effects in laboratory rodents and rabbits. Lab Anim 1984; 18: 143–146.

16.

Nicklas

Baneux

Boot

et al.

Recommendations for the health monitoring of rodent and rabbit colonies in breeding and experimental units. Lab Anim 2002; 36: 20–42.

17.

Mahler

(Convenor) Berard

Feinstein

et al.

FELASA recommendations for the health monitoring of mouse, rat, hamster, guineapig and rabbit colonies in breeding and experimental units. Lab Anim 2014; 48: 178–192.

18.

Boas

Villiger

. Clinical actions of fentanyl and buprenorphine. The significance of receptor binding. Br J Anaesth 1985; 57: 192–196.

19.

Walker

Curtis

Hearse

et al.

The Lambeth Conventions: guidelines for the study of arrhythmias in ischaemia infarction, and reperfusion. Cardiovasc Res 1988; 22: 447–455.

20.

Schultz

Rose

Yao

Gross

. Evidence for involvement of opioid receptors in ischemic preconditioning in rat hearts. Am J Physiol 1995; 268: H2157–H2161.

21.

Miki

Cohen

Downey

. Opioid receptor contributes to ischemic preconditioning through protein kinase C activation in rabbits. Mol Cell Biochem 1998; 186: 3–12.

22.

Jang

Wang

Mueller

Norfleet

. Postconditioning prevents reperfusion injury by activating delta-opioid receptors. Anesthesiology 2008; 108: 243–250.

23.

Shen

Wang

. Sufentanil postconditioning protects the myocardium from ischemia–reperfusion via PI3K/Akt-GSK-3beta pathway. J Surg Res 2012; 178: 563–570.

24.

Murry

Jennings

Reimer

. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986; 74: 1124–1136.

25.

Zhao

Corvera

Halkos

et al.

Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol 2003; 285: H579–H588.

26.

Bell

Sack

Patel

Opie

Yellon

. Delta opioid receptor stimulation mimics ischemic preconditioning in human heart muscle. J Am Coll Cardiol 2000; 36: 2296–2302.

27.

Schultz

Hsu

Gross

. Ischemic preconditioning and morphine-induced cardioprotection involve the delta (delta)-opioid receptor in the intact rat heart. J Mol Cell Cardiol 1997; 29: 2187–2195.

28.

Wang

Pei

Wong

. Kappa- but not delta-opioid receptors mediate effects of ischemic preconditioning on both infarct and arrhythmia in rats. Am J Physiol Heart Circ Physiol 2001; 280: H384–H391.

29.

Zhu

Zhang

Liu

Fang

. Sufentanil limits the myocardial infarct size by preservation of the phosphorylated connexin 43. Int Immunopharmacol 2012; 13: 341–346.

30.

Lemoine

Zhu

Massetti

Gerard

Hanouz

. Continuous administration of remifentanil and sufentanil induces cardioprotection in human myocardium, in vitro. Acta Anaesthesiol Scand 2011; 55: 758–764.

31.

Wong

Jiang

Irwin

. Remifentanil post-conditioning attenuates cardiac ischemia–reperfusion injury via kappa or delta opioid receptor activation. Acta Anaesthesiol Scand 2010; 54: 510–518.

32.

Wan

Zhen

et al.

The effect of butorphanol postconditioning on myocardial ischaemia reperfusion injury in rats. Interact Cardiovasc Thorac Surg 2014; 18: 308–312.

33.

Schultz

Hsu

Gross

. Ischemic preconditioning in the intact rat heart is mediated by delta1- but not mu- or kappa-opioid receptors. Circulation 1998; 97: 1282–1289.

34.

Wijeysundera

Naik

Beattie

. Alpha-2 adrenergic agonists to prevent perioperative cardiovascular complications: a meta-analysis. Am J Med 2003; 114: 742–752.

35.

Virtanen

. Pharmacological profiles of medetomidine and its antagonist, atipamezole. Acta Vet Scand Suppl 1989; 85: 29–37.

36.

Sinclair

. A review of the physiological effects of alpha2-agonists related to the clinical use of medetomidine in small animal practice. Can Vet J 2003; 44: 885–897.

37.

Savola

Virtanen

. Central alpha 2-adrenoceptors are highly stereoselective for dexmedetomidine, the dextro enantiomer of medetomidine. Eur J Pharmacol 1991; 195: 193–199.

38.

Cale

Mendes

Brito

et al.

Resting heart rate is a powerful predictor of arrhythmic events in patients with dilated cardiomyopathy and implantable cardioverter–defibrillator. Rev Port Cardiol 2011; 30: 199–212.

39.

Andrews

Reimold

Berlin

Antman

. Prevention of supraventricular arrhythmias after coronary artery bypass surgery. A meta-analysis of randomized control trials. Circulation 1991; 84(5 Suppl): III236–III244.

40.

Crystal

Connolly

Sleik

Ginger

Yusuf

. Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis. Circulation 2002; 106: 75–80.

41.

Ibanez

Macaya

Sanchez-Brunete

et al.

Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the effect of metoprolol in cardioprotection during an acute myocardial infarction (METOCARD–CNIC) trial. Circulation 2013; 128: 1495–1503.

42.

London

. Beta blockers and alpha2 agonists for cardioprotection. Best Pract Res Clin Anaesthesiol 2008; 22: 95–110.